NZ708016A - Lyophilized preparations of melphalan flufenamide - Google Patents
Lyophilized preparations of melphalan flufenamideInfo
- Publication number
- NZ708016A NZ708016A NZ708016A NZ70801613A NZ708016A NZ 708016 A NZ708016 A NZ 708016A NZ 708016 A NZ708016 A NZ 708016A NZ 70801613 A NZ70801613 A NZ 70801613A NZ 708016 A NZ708016 A NZ 708016A
- Authority
- NZ
- New Zealand
- Prior art keywords
- melphalan flufenamide
- lyophilized preparations
- directed
- pharmaceutical preparations
- lyophilized pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261719184P | 2012-10-26 | 2012-10-26 | |
| SE1251211 | 2012-10-26 | ||
| PCT/SE2013/051246 WO2014065751A1 (en) | 2012-10-26 | 2013-10-24 | Lyophilized preparations of melphalan flufenamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ708016A true NZ708016A (en) | 2018-02-23 |
Family
ID=50544986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ708016A NZ708016A (en) | 2012-10-26 | 2013-10-24 | Lyophilized preparations of melphalan flufenamide |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10285946B2 (enExample) |
| EP (2) | EP3628318A1 (enExample) |
| JP (1) | JP6284945B2 (enExample) |
| KR (1) | KR102205592B1 (enExample) |
| CN (2) | CN104994847B (enExample) |
| AU (1) | AU2013335359B2 (enExample) |
| BR (1) | BR112015009280B1 (enExample) |
| CA (1) | CA2889753C (enExample) |
| CY (1) | CY1122483T1 (enExample) |
| IL (1) | IL238398B (enExample) |
| MX (1) | MX365205B (enExample) |
| NZ (1) | NZ708016A (enExample) |
| PL (1) | PL2928463T3 (enExample) |
| RS (1) | RS60068B1 (enExample) |
| RU (1) | RU2643762C2 (enExample) |
| SI (1) | SI2928463T1 (enExample) |
| SM (1) | SMT202000058T1 (enExample) |
| WO (1) | WO2014065751A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3228319T1 (sl) | 2011-04-28 | 2020-10-30 | Oncopeptides Ab | Liofiliziran pripravek citotoksičnih dipeptidov |
| JP6284945B2 (ja) | 2012-10-26 | 2018-02-28 | オンコペプティデス エービーＯｎｃｏｐｅｐｔｉｄｅｓ ＡＢ | メルファランフルフェナミドの凍結乾燥製剤 |
| GB201507903D0 (en) | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
| GB201521217D0 (en) | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
| MX2020010031A (es) | 2018-03-29 | 2021-01-08 | Airway Therapeutics Inc | Sistemas y metodos para caracterizar oligomeros de proteina surfactante d (sp-d). |
| RU2020131642A (ru) | 2018-03-29 | 2022-04-29 | Эйрвэй Терапьютикс, Инк. | Способы и композиции, содержащие сурфактантный белок d (sp-d) |
| WO2020079165A1 (en) * | 2018-10-18 | 2020-04-23 | Oncopeptides Ab | Compounds containing deuterium |
| WO2020201542A1 (en) | 2019-04-03 | 2020-10-08 | Oncopeptides Ab | Treatment of al amyloidosis with melflufen |
| GB201905477D0 (en) | 2019-04-17 | 2019-05-29 | Oncopeptides Ab | Novel formulations |
| WO2021053185A1 (en) | 2019-09-20 | 2021-03-25 | Oncopeptides Ab | Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma |
| GB202109894D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202109896D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| US20240307480A1 (en) | 2021-07-08 | 2024-09-19 | Oncopeptides Ab | Melflufen for use in the treatment of multiple myeloma |
| GB202109895D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| KR102757193B1 (ko) * | 2021-10-19 | 2025-01-21 | 단국대학교 천안캠퍼스 산학협력단 | 피리미딘-2,4-다이온 유도체를 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물 |
| GB202204171D0 (en) | 2022-03-24 | 2022-05-11 | Oncopeptides Ab | Novel formulations |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8727157D0 (en) | 1987-11-19 | 1987-12-23 | Wellcome Found | Pharmaceutical formulations |
| US6992207B2 (en) * | 2000-06-13 | 2006-01-31 | Oncopeptides Ab | Melphalan derivatives and their use as cancer chemotherapeutic drugs |
| SE0002202D0 (sv) | 2000-06-13 | 2000-06-13 | Karolinska Innovations Ab | New peptides |
| JP2005508220A (ja) * | 2001-10-24 | 2005-03-31 | パーリ・ゲーエムベーハー | 薬用組成物調製用具 |
| US6780324B2 (en) | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US20040034099A1 (en) * | 2002-06-27 | 2004-02-19 | Ramsey Beverly J. | Pharmaceutical composition |
| US20050152979A1 (en) | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
| EP1674098A1 (en) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
| GB0522082D0 (en) | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| US7754720B2 (en) * | 2006-07-07 | 2010-07-13 | Gilead Sciences, Inc. | Pyridazine compound and use thereof |
| PT2101731T (pt) * | 2006-11-21 | 2018-04-18 | Jina Pharmaceuticals Inc | Endoxifeno para utilização no tratamento de cancro |
| CN101584669B (zh) * | 2009-06-19 | 2010-12-29 | 江苏奥赛康药业有限公司 | 美法仑冻干粉针剂 |
| WO2011078782A1 (en) * | 2009-12-22 | 2011-06-30 | Oncopeptides Ab | A composition comprising of melphalan derivatives and gemcitabine or etoposide useful in the treatment of cancer |
| AR077384A1 (es) | 2010-07-05 | 2011-08-24 | Eriochem Sa | Una formulacion farmaceutica inyectable de melfalano. |
| HRP20201241T1 (hr) | 2011-04-15 | 2020-11-27 | Janssen Pharmaceutica N.V. | Nanosuspenzije lijeka osušene zamrzavanjem |
| SI3228319T1 (sl) | 2011-04-28 | 2020-10-30 | Oncopeptides Ab | Liofiliziran pripravek citotoksičnih dipeptidov |
| JP6284945B2 (ja) | 2012-10-26 | 2018-02-28 | オンコペプティデス エービーＯｎｃｏｐｅｐｔｉｄｅｓ ＡＢ | メルファランフルフェナミドの凍結乾燥製剤 |
-
2013
- 2013-10-24 JP JP2015539556A patent/JP6284945B2/ja active Active
- 2013-10-24 RU RU2015118581A patent/RU2643762C2/ru active
- 2013-10-24 SI SI201331667T patent/SI2928463T1/sl unknown
- 2013-10-24 RS RS20200116A patent/RS60068B1/sr unknown
- 2013-10-24 CN CN201380063592.5A patent/CN104994847B/zh active Active
- 2013-10-24 KR KR1020157013026A patent/KR102205592B1/ko active Active
- 2013-10-24 SM SM20200058T patent/SMT202000058T1/it unknown
- 2013-10-24 CA CA2889753A patent/CA2889753C/en active Active
- 2013-10-24 WO PCT/SE2013/051246 patent/WO2014065751A1/en not_active Ceased
- 2013-10-24 US US14/438,473 patent/US10285946B2/en active Active
- 2013-10-24 EP EP19207842.6A patent/EP3628318A1/en active Pending
- 2013-10-24 AU AU2013335359A patent/AU2013335359B2/en not_active Ceased
- 2013-10-24 PL PL13849763T patent/PL2928463T3/pl unknown
- 2013-10-24 MX MX2015005217A patent/MX365205B/es active IP Right Grant
- 2013-10-24 NZ NZ708016A patent/NZ708016A/en unknown
- 2013-10-24 CN CN201810826176.0A patent/CN108685860B/zh active Active
- 2013-10-24 BR BR112015009280-2A patent/BR112015009280B1/pt active IP Right Grant
- 2013-10-24 EP EP13849763.1A patent/EP2928463B1/en active Active
-
2015
- 2015-04-21 IL IL238398A patent/IL238398B/en active IP Right Grant
-
2016
- 2016-05-09 US US15/149,975 patent/US10285947B2/en active Active
-
2020
- 2020-01-13 CY CY20201100028T patent/CY1122483T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX365205B (es) | Preparaciones liofilizadas de melfalán flufenamida. | |
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| EA201992133A1 (ru) | Производные пиперидино-пиримидина для лечения вирусных инфекций | |
| MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| GB201118656D0 (en) | New compounds | |
| MX366899B (es) | Nuevos compuestos. | |
| GB201209613D0 (en) | New compounds | |
| EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
| MX361585B (es) | Derivados 2-aminoquinazolínicos sustituidos heterocíclicos para el tratamiento de infecciones víricas. | |
| MX349004B (es) | Nuevos compuestos. | |
| PH12015500724A1 (en) | 1, 2, 4-triazine derivatives for the treatment of viral infections | |
| TN2012000611A1 (en) | Formulations of rifaximin and uses thereof | |
| IN2013MU03583A (enExample) | ||
| UA107550C2 (uk) | Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів | |
| MY186134A (en) | Curcumin-peptide conjugates and formulations thereof | |
| WO2013096335A8 (en) | ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT | |
| PH12015502564A1 (en) | Pyridone derivatives for the treatment of viral infections and further diseases | |
| MX368943B (es) | Formulaciones de tripeptido liofilizado estables en almacenamiento. | |
| MX355719B (es) | Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 OCT 2019 BY CPA GLOBAL Effective date: 20180920 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 OCT 2020 BY CPA GLOBAL Effective date: 20190919 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 OCT 2021 BY CPA GLOBAL Effective date: 20200917 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 OCT 2022 BY CPA GLOBAL Effective date: 20210916 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 OCT 2023 BY CPA GLOBAL Effective date: 20220923 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 OCT 2024 BY CPA GLOBAL Effective date: 20230921 |
|
| ASS | Change of ownership |
Owner name: ONCOPEPTIDES INNOVATION AB, SE Effective date: 20240417 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240919 |